RecruitingPhase 2NCT06701812

Digoxin Medulloblastoma Study

Evaluation of Digoxin for Relapsed Non-WNT, Non-SHH Medulloblastoma

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Enrollment

23 participants

Start Date

Jan 15, 2026

Study Type

INTERVENTIONAL

Conditions

Medulloblastoma Medulloblastoma, Non-WNT/Non-SHH

Summary

The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.

Eligibility

Min Age: 12 MonthsMax Age: 30 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Digoxin for people with medulloblastoma and medulloblastoma, non-wnt/non-shh. The study is currently recruiting participants at 15 locations. People eligible for this study include aged 12 Months to 30 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDigoxin

2.5-10 mcg/kg/day orally divided twice daily or once daily based on age on a continuous dosing schedule.

Locations(15)

University of Alabama at Birmingham Children's of Alabama

Birmingham, Alabama, United States

Arkansas Childrens Hospital

Little Rock, Arkansas, United States

Connecticut Children's Medical Center

Hartford, Connecticut, United States

Children's National Medical Center

Washington D.C., District of Columbia, United States

Nemours Jacksonville

Jacksonville, Florida, United States

University of Miami

Miami, Florida, United States

Johns Hopkins All Children's

St. Petersburg, Florida, United States

St. Joseph's Children's Hospital

Tampa, Florida, United States

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, United States

Washington University St. Louis

St Louis, Missouri, United States

Montefiore Medical Center

The Bronx, New York, United States

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, United States

Levine Cancer Institute

Charlotte, North Carolina, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

UT Southwestern

Dallas, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06701812

Related Trials

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

NCT061615191 location

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

NCT052782084 locations

CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation

NCT070853251 location

Parental Distress and Treatment Adherence in Pediatric Recurrent Medulloblastoma

NCT076604581 location

PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

NCT066396073 locations